pharmaceutical preparations for - (1) the treatment of psychoneurotic patients with depression and/or anxiety; depression and/or anxiety associated with alcoholism; depression and/or anxiety associated with organic disease; psychotic depressive disorders associated with anxiety including involutional depression and manic-depressive disorders; (2) therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia"; (3) the management of exogenous obesity as a short-term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction; (4) the treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible; (5) the treatment of moderate to severe vasomotor symptoms associated with the menopause; atrophic vaginitis; kraurosis vulvae; female hypogonadism; female castration; primary ovarian failure; breast cancer (for palliation only) in appropriately selected women and men with metastatic disease; prostatic carcinoma-palliative therapy of advanced disease